Baird Medical Advances Thyroid MWA Training and Academic Exchange with Leading Harvard Professor
Baird Medical (NASDAQ: BDMD), a leader in Microwave Ablation (MWA) technology, hosted an advanced training session and academic exchange in New Orleans. The program featured collaboration between Dr. Emad Kandil, Professor at Tulane University School of Medicine, and Dr. Gregory Randolph, Professor at Harvard Medical School and Claire and John Bertucci Endowed Chair in Thyroid Surgical Oncology.
During the May 9, 2025 event, the experts engaged in academic discussions on thyroid-focused topics, conducted clinical observations, and performed hands-on procedures. The initiative is part of Baird Medical's strategy to promote excellence in thyroid care through partnerships with medical leaders and support global adoption of minimally invasive therapies.
Baird Medical (NASDAQ: BDMD), leader nelle tecnologie di Ablazione a Microonde (MWA), ha organizzato una sessione di formazione avanzata e uno scambio accademico a New Orleans. Il programma ha visto la collaborazione tra il Dott. Emad Kandil, Professore presso la Tulane University School of Medicine, e il Dott. Gregory Randolph, Professore alla Harvard Medical School e titolare della cattedra Claire and John Bertucci in Chirurgia Oncologica della Tiroide.
Durante l'evento del 9 maggio 2025, gli esperti hanno partecipato a discussioni accademiche su temi focalizzati sulla tiroide, effettuato osservazioni cliniche e svolto procedure pratiche. Questa iniziativa fa parte della strategia di Baird Medical volta a promuovere l'eccellenza nella cura della tiroide attraverso collaborazioni con leader medici e a sostenere l'adozione globale di terapie minimamente invasive.
Baird Medical (NASDAQ: BDMD), líder en tecnología de Ablación por Microondas (MWA), organizó una sesión avanzada de capacitación e intercambio académico en Nueva Orleans. El programa contó con la colaboración del Dr. Emad Kandil, Profesor en la Escuela de Medicina de la Universidad de Tulane, y el Dr. Gregory Randolph, Profesor en la Escuela de Medicina de Harvard y titular de la Cátedra Claire and John Bertucci en Oncología Quirúrgica de Tiroides.
Durante el evento del 9 de mayo de 2025, los expertos participaron en discusiones académicas sobre temas relacionados con la tiroides, realizaron observaciones clínicas y llevaron a cabo procedimientos prácticos. Esta iniciativa forma parte de la estrategia de Baird Medical para promover la excelencia en el cuidado de la tiroides mediante colaboraciones con líderes médicos y apoyar la adopción global de terapias mínimamente invasivas.
Baird Medical(NASDAQ: BDMD)는 마이크로웨이브 절제(MWA) 기술 분야의 선두주자로서 뉴올리언스에서 고급 교육 세션과 학술 교류를 주최했습니다. 이 프로그램은 튤레인 대학교 의과대학의 Emad Kandil 박사와 하버드 의과대학의 교수이자 Claire and John Bertucci 갑상선 외과 종양학 기금석좌인 Gregory Randolph 박사의 협력으로 진행되었습니다.
2025년 5월 9일 행사에서 전문가들은 갑상선을 주제로 한 학술 토론에 참여하고 임상 관찰을 수행했으며 직접 시술을 진행했습니다. 이 이니셔티브는 의료 리더들과의 파트너십을 통해 갑상선 치료의 우수성을 촉진하고 최소 침습 치료법의 전 세계적 채택을 지원하려는 Baird Medical의 전략의 일환입니다.
Baird Medical (NASDAQ : BDMD), leader dans la technologie d'ablation par micro-ondes (MWA), a organisé une session de formation avancée et un échange académique à La Nouvelle-Orléans. Le programme a mis en lumière la collaboration entre le Dr Emad Kandil, professeur à la Tulane University School of Medicine, et le Dr Gregory Randolph, professeur à la Harvard Medical School et titulaire de la chaire Claire and John Bertucci en oncologie chirurgicale de la thyroïde.
Lors de l'événement du 9 mai 2025, les experts ont participé à des discussions académiques sur des sujets liés à la thyroïde, réalisé des observations cliniques et effectué des procédures pratiques. Cette initiative s'inscrit dans la stratégie de Baird Medical visant à promouvoir l'excellence dans les soins de la thyroïde par des partenariats avec des leaders médicaux et à soutenir l'adoption mondiale de thérapies peu invasives.
Baird Medical (NASDAQ: BDMD), ein führendes Unternehmen im Bereich der Mikrowellenablation (MWA)-Technologie, veranstaltete eine Fortgeschrittenenschulung und einen akademischen Austausch in New Orleans. Das Programm beinhaltete eine Zusammenarbeit zwischen Dr. Emad Kandil, Professor an der Tulane University School of Medicine, und Dr. Gregory Randolph, Professor an der Harvard Medical School und Inhaber des Claire and John Bertucci Lehrstuhls für Schilddrüsenchirurgische Onkologie.
Während der Veranstaltung am 9. Mai 2025 führten die Experten akademische Diskussionen zu schilddrüsenspezifischen Themen, klinische Beobachtungen und praktische Verfahren durch. Diese Initiative ist Teil der Strategie von Baird Medical, Exzellenz in der Schilddrüsenversorgung durch Partnerschaften mit medizinischen Führungspersönlichkeiten zu fördern und die weltweite Einführung minimalinvasiver Therapien zu unterstützen.
- None.
- None.
The program was led by Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, a leading figure in thyroid ablation and endocrine surgery. He was joined by Dr. Gregory Randolph, Professor of Otolaryngology–Head and Neck Surgery at Harvard Medical School and the Claire and John Bertucci Endowed Chair in Thyroid Surgical Oncology. Visiting Tulane as a Distinguished Professor on May 9, 2025, Dr. Randolph engaged in academic discussions with Dr. Kandil on a range of thyroid-focused topics.
Following their exchange, Dr. Randolph participated in clinical observations and hands-on procedures alongside Dr. Kandil. The two experts also explored emerging technologies and discussed opportunities for future research collaboration in the field of thyroid surgery.
This initiative is part of Baird Medical's broader strategy to promote excellence in thyroid care by partnering with world-class medical leaders. Through advanced training and academic partnerships, the Company continues to support the global adoption of innovative, minimally invasive therapies.
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the
The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-advances-thyroid-mwa-training-and-academic-exchange-with-leading-harvard-professor-302451936.html
SOURCE BDMD
FAQ
What was the purpose of BDMD's academic exchange with Harvard Professor Dr. Randolph?
Who were the key medical experts involved in Baird Medical's thyroid MWA training session?
When and where did Baird Medical host the thyroid MWA training session?
What is Baird Medical's (BDMD) main technology focus?
